59 results
8-K
EX-3.1
PRME
Prime Medicine Inc
21 May 24
Amendments to Articles of Incorporation or Bylaws
4:03pm
or beneficially by the Proposing Person) (such person or persons, the “Responsible Person”), (f) any pending or threatened litigation in which
8-K
EX-99.1
PRME
Prime Medicine Inc
10 May 24
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
8:05am
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied
PRE 14A
PRME
Prime Medicine Inc
19 Apr 24
Preliminary proxy
4:07pm
could prevent protracted or otherwise meritless litigation that distracts from our primary objective of creating stockholder value over the long term
8-K
EX-99.1
qvcqlf3h
1 Mar 24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
8:01am
8-K
g45oc4kofo83
16 Feb 24
Entry into a Material Definitive Agreement
6:23am
8-K
EX-1.1
fks5ln84
16 Feb 24
Entry into a Material Definitive Agreement
6:23am
8-K
1qxbhkags281u3ekz6
14 Feb 24
Results of Operations and Financial Condition
4:12pm
8-K
EX-99.1
1wh6acbe
8 Jan 24
Regulation FD Disclosure
8:01am
S-3
EX-1.2
tgmnt3mo
3 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
g0y7tt
3 Nov 23
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
4:06pm
8-K
EX-99.2
wtbm1ju0
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
ssvxw4u 54jksb
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
jq9hfv8
17 May 23
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
7:09am
8-K
EX-99.1
p3dimdab
11 May 23
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
8:05am